Ascelia Pharma AB (ACE) Stock Price & Analysis

ACE Stock Chart & Stats

SEK 0.58SEK 0.00(0.00%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: SEK 0.55 - SEK 0.59
52-Week Range: SEK 0.46 - SEK 3.55
Previous Close: SEK 0.58
Volume: 171.87K
Average Volume (3M): 1.18M
Market Cap: SEK 77.45M
Enterprise Value: SEK 352.94M
Total Cash (Recent Filing): SEK 38.05M
Total Debt (Recent Filing): SEK 490.00K
Price to Earnings (P/E): ―
Beta: 0.62
Next Earnings: Nov 05, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage limits interest and refinancing pressure while preserving flexibility to fund development or respond to setbacks. Although the company remains loss-making, its conservative debt profile reduces balance-sheet risk over the next several quarters.

Improving Losses And Cash Burn

The improvement in operating cash burn from 2023 indicates progress in controlling cash usage, even though funding needs remain substantial. If sustained, a lower burn rate could extend financial runway and make future capital requirements more manageable.

Focused Oncology Imaging Candidate

Orviglance addresses a defined oncology imaging use case and is designed for patients where gadolinium-based agents may be undesirable. If clinical and regulatory objectives are achieved, this focused product could support differentiated adoption in liver MRI workflows.

Bears Say

Pre-Revenue Business

The company has not yet established recurring product revenue, so its business model remains dependent on development success before commercial economics can emerge. The absence of revenue also means fixed development costs currently translate directly into continued operating losses.

Persistent Cash Burn

Ongoing negative operating and free cash flow requires Ascelia Pharma to keep funding development before revenues arrive. Continued external financing can dilute existing shareholders or constrain programs if capital becomes less available, creating a durable execution risk.

Eroding Capital Base

Sustained losses are reducing the equity base and producing strongly negative returns on shareholder capital. This weakens financial resilience over time and increases the importance of successful commercialization or additional financing to support the development plan.

Ascelia Pharma AB News

Ascelia Pharma Charts New Path for Orviglance After FDA Meeting

Ascelia Pharma AB ( ($SE:ACE) ) just unveiled an announcement. Ascelia Pharma has received official minutes from its Type A meeting with the U.S. FDA regarding the Complete Response Letter

3w ago7ZA ACE

Ascelia Pharma’s Orviglance Study Published in Leading MRI Journal

Ascelia Pharma AB ( ($SE:ACE) ) just unveiled an update. Ascelia Pharma AB, a Malmö-based biotech company listed on Nasdaq Stockholm and focused on orphan oncology treatments, is developing two

1M ago7ZA ACE

Ascelia Pharma Holds FDA Type A Meeting on Orviglance NDA

Ascelia Pharma AB ( ($SE:ACE) ) has issued an update. Ascelia Pharma has completed a Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response

1M ago7ZA ACE

Ascelia Pharma Tightens Costs After FDA Setback on Orviglance

An announcement from Ascelia Pharma AB ( ($SE:ACE) ) is now available. Ascelia Pharma reported that its primary focus in the first half of 2026 has been advancing Orviglance through

2M ago7ZA ACE

Ascelia Pharma Secures FDA Type A Meeting on Orviglance NDA

An announcement from Ascelia Pharma AB ( ($SE:ACE) ) is now available. Ascelia Pharma said the U.S. Food and Drug Administration has scheduled a Type A meeting on September 9,

2M ago7ZA ACE

Ascelia Pharma Restructures and Cuts Costs to Sharpen Focus on Orviglance

Ascelia Pharma AB ( ($SE:ACE) ) just unveiled an update. Ascelia Pharma has announced organizational changes and cost reduction measures, including the planned departure of Chief Financial Officer Anton Hansson

3M ago7ZA ACE

Ascelia Pharma Defends Orviglance Data After FDA Complete Response Letter

The latest announcement is out from Ascelia Pharma AB ( ($SE:ACE) ). Ascelia Pharma has provided an update on its MRI contrast agent candidate Orviglance after the U.S. Food and

3M ago7ZA ACE

Ascelia Pharma Receives FDA Complete Response Letter on Orviglance NDA

Ascelia Pharma AB ( ($SE:ACE) ) has issued an announcement. Ascelia Pharma AB, a Malmö-based biotech company focused on orphan oncology treatments for rare cancer-related conditions, is advancing a pipeline

4M ago7ZA ACE

Ascelia Pharma Bolsters Orviglance Franchise with New Patent Filing

An update from Ascelia Pharma AB ( ($SE:ACE) ) is now available. Ascelia Pharma has filed a new patent application covering packaging and manufacturing innovations for its first-in-class liver imaging

4M ago7ZA ACE

Ascelia Showcases Orviglance MRI Data at ESGAR 2026 Amid FDA Review

The latest announcement is out from Ascelia Pharma AB ( ($SE:ACE) ). Ascelia Pharma said new clinical data for its manganese-based oral MRI contrast agent Orviglance are being presented today

4M ago7ZA ACE

ACE FAQ

What was Ascelia Pharma AB’s price range in the past 12 months?

Ascelia Pharma AB lowest stock price was kr 0.46 and its highest was kr 3.55 in the past 12 months.

What is Ascelia Pharma AB’s market cap?

Ascelia Pharma AB’s market cap is kr 77.45M.

When is Ascelia Pharma AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Ascelia Pharma AB’s earnings last quarter?

Ascelia Pharma AB released its earnings results on Aug 20, 2026. The company reported -kr 0.093 earnings per share for the quarter.

Is Ascelia Pharma AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Ascelia Pharma AB pay dividends?

Ascelia Pharma AB does not currently pay dividends.

What is Ascelia Pharma AB’s EPS estimate?

Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ascelia Pharma AB have?

Ascelia Pharma AB has 133,535,460 shares outstanding.

What happened to Ascelia Pharma AB’s price movement after its last earnings report?

Ascelia Pharma AB reported an EPS of -kr 0.093 in its last earnings report. Following the earnings report the stock price went up 7.273%.

Which hedge fund is a major shareholder of Ascelia Pharma AB?

Currently, no hedge funds are holding shares in SE:ACE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description